YY/T 1233-2024 PDF English
Price & Delivery
US$185.00 · In stock · Download in 9 secondsYY/T 1233-2024: Cardiac troponin detection reagent kit (labelling immunoassay)
Delivery: 9 seconds. True-PDF full-copy in English & invoice will be downloaded + auto-delivered via email. See step-by-step procedure
Status: Valid
YY/T 1233: Historical versions
| Standard ID | USD | BUY PDF | Delivery | Standard Title (Description) | Status |
| YY/T 1233-2024 | 185 | Add to Cart | Auto, 9 seconds. | Cardiac troponin detection reagent kit (labelling immunoassay) | Valid |
| YY/T 1233-2014 | 140 | Add to Cart | Auto, 9 seconds. | Cardiac troponin-I (cTnl) quantitative detection reagent (kit) (Chemiluminescent immunoassay) | Valid |
Click to Preview this PDF
YY/T 1233-2024: Cardiac troponin detection reagent kit (labelling immunoassay)
---This is an excerpt. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.), auto-downloaded/delivered in 9 seconds, can be purchased online: https://www.ChineseStandard.net/PDF.aspx/YYT1233-2024YY PHARMACEUTICAL INDUSTRY STANDARD ICS 11.100.10 CCS C 44 Replacing YY/T 1233-2014 Cardiac troponin detection reagent kit (labelling immunoassay) Issued on: SEPTEMBER 29, 2024 Implemented on: OCTOBER 15, 2025 Issued by. National Medical products Administration
Table of Contents
Preface... 3 1 Scope... 5 2 Normative References... 5 3 Terms and Definitions... 6 4 Requirements... 6 5 Test Methods... 10 6 Identification, Labeling, and Instructions for Use... 14 7 Packaging, Transport, and Storage... 14 References... 15 Cardiac troponin detection reagent kit (labelling immunoassay)1 Scope
This document specifies the requirements, labeling, instructions for use, packaging, transportation, and storage for Cardiac troponin detection reagent kit (labelling immunoassay), and describes the corresponding test methods. This document applies to kits intended for the in vitro quantitative detection of cardiac troponin I (hereinafter referred to as cTnI) and cardiac troponin T (hereinafter referred to as cTnT) in human serum, plasma, or whole blood. The methodologies covered include enzyme-linked immunoassay, enzymatic and non-enzymatic chemiluminescence, electrochemiluminescence, time-resolved fluorescence immunoassay, and others. This document does not apply to. -- Qualitative or semi-quantitative reagents labeled with colloidal gold or other methods (e.g., test strips, biochips, etc.); -- Various radioimmunoassay or immunoradiometric assay kits labeled with radioisotopes; -- cTnI or cTnT calibrators and quality control materials intended for separate sale.2 Normative References
The contents of the following documents constitute indispensable provisions of this document through normative reference therein. For dated references, only the edition cited applies to this document. For undated references, the latest edition (including all amendments) applies to this document. GB/T 191 Packaging - Pictorial marking for handling of goods GB/T 21415 In vitro diagnostic medical devices - Metrological traceability of values assigned to calibrators and control materials GB/T 29791.1 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1.Terms, definitions and general requirements GB/T 29791.2 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2.In vitro diagnostic reagents for professional use3 Terms and Definitions
The terms and definitions defined in GB/T 29791.1, as well as the following terms and definitions, apply to this document. 3.1 High-sensitivity cardiac troponin detection; hs-cTn It is a measurement method that can consistently detect cardiac troponin (cTn) in the peripheral blood of more than 50% of healthy adult males and females, with the measurement results being greater than or equal to the limit of detection, and for which the coefficient of variation (CV) of the measurement results is less than or equal to 10% at the 99th percentile upper reference limit (99th URL) of the healthy population. Note 1.The 99th URL refers to the cTn concentration value obtained by arranging the cTn concentration values of apparently healthy individuals in ascending order; the value located at the 99th position (specifically, the mean of the values at the 99th and 100th positions) is termed the 99th percentile upper reference limit for apparently healthy individuals. Note 2.The 99th URL is a recognized cutoff point for myocardial injury and serves as an essential cutoff value for the diagnosis of myocardial infarction. Note 3.Both hs-cTn and conventional cTn detection methods (hereinafter referred to as con-cTn) target cTn as the analyte. The distinction lies in the sensitivity of the detection system, rather than in the substance being measured.4 Requirements
4.1 Appearance The manufacturer shall establish appearance requirements for the product. These requirements shall include. a) The kit shall contain all components; there shall be no liquid leakage; both the inner and outer packaging shall be intact; and labels and markings shall be clear. b) Where applicable, liquid reagents shall be homogeneous solutions, free from precipitates and flocculent matter. c) Where applicable, lyophilized products, upon reconstitution, shall form homogeneous solutions free from precipitates, flocculent matter, etc. 4.2 Traceability In accordance with GB/T 21415 and relevant regulations, the manufacturer shall provide information regarding the source of the cTnI and/or cTnT calibrators used, the value assignment process for traceability, corresponding requirements, uncertainty estimates, and other relevant details. 4.3 Accuracy Accuracy shall meet one of the following requirements. a) Relative Bias. When testing Certified Reference Materials (CRMs) or other recognized reference materials, the relative bias of the measurement results shall meet the acceptable criteria for cTn assays; alternatively, when testing accuracy control materials provided by the manufacturer that demonstrate commutability, the relative bias of the measurement results shall not exceed ±10%. Product calibrators associated with the reagent under evaluation, as well as quality control materials with assigned values specific to the reagent's detection system, shall not be used for accuracy evaluation. b) Recovery. Within the range of [85.0%, 115.0%]. c) Comparison Study. When compared against an analytical system designated by the manufacturer that possesses metrological traceability, the correlation coefficient (r) shall be no less than 0.975, and the slope shall fall within the range of [0.9, 1.1]. Note. Where applicable, priority shall be given to the use of Certified Reference Materials (CRM) or other recognized reference materials as specified in 4.3a). 4.4 Detection Limit The manufacturer shall specify the detection limit of the product; the detection limit claimed by the manufacturer shall meet the following requirements. a) For conventional cTnI assay kits (hereinafter referred to as con-cTnI), the detection limit shall not exceed 0.05 ng/mL. b) For conventional cTnT assay kits (hereinafter referred to as con-cTnT), the detection limit shall not exceed 0.05 ng/mL. c) For high-sensitivity cTnI assay kits (hereinafter referred to as hs-cTnI), the detection limit shall not exceed 5.0 ng/L. d) For high-sensitivity cTnT assay kits (hereinafter referred to as hs-cTnT), the detection limit shall not exceed 8.0 ng/L. Note. Concentration unit conversion formula. 1 pg/mL = 1 ng/L = 0.001 ng/mL = 0.001 μg/L. 4.5 Linearity The manufacturer shall specify the product's linear range. The linear range claimed by the manufacturer shall comply with the following requirements. a) For con-cTnI, the upper limit of the linear range shall be no less than 50 ng/mL, and the lower limit shall be no higher than the manufacturer's claimed limit of quantitation. Within the linear range specified by the manufacturer, the linear correlation coefficient (r) shall be ≥ 0.990. b) For con-cTnT, the upper limit of the linear range shall be no less than 10 ng/mL, and the lower limit shall be no higher than the manufacturer's claimed limit of quantitation. Within the linear range specified by the manufacturer, the linear correlation coefficient (r) shall be ≥ 0.990. c) For hs-cTnI, the upper limit of the linear range shall be no less than 10,000 ng/L, and the lower limit shall be no higher than the manufacturer's claimed limit of quantitation. Within the linear range specified by the manufacturer, the linear correlation coefficient (r) shall be ≥ 0.990. d) For hs-cTnT, the upper limit of the linear range shall be no less than 8,000 ng/L, and the lower limit shall be no higher than the manufacturer's claimed limit of quantitation. Within the linear range specified by the manufacturer, the linear correlation coefficient (r) shall be ≥ 0.990. 4.6 Repeatability Within the linear range claimed by the manufacturer. for hs-cTn kits, samples at three concentration levels (high, medium, and low) shall be selected; for con-cTn kits, samples at least two concentration levels shall be selected. Each sample concentration level shall be tested in replicate at least 10 times, and the coefficient of variation (CV) of the test results shall be no greater than 10%. The samples tested shall include those at a concentration level near the 99th percentile Upper Reference Limit (99th URL) for healthy individuals—for example, within the range of 99th URL ± 20%. 4.7 Inter-batch Precision Within the linear range claimed by the manufacturer, samples at three concentration levels (high, medium, and low) shall be selected for hs-cTn kits, while samples at at least two concentration levels shall be selected for con-cTn kits. The same sample shall be tested using kits from three different lot numbers; the coefficient of variation (CV) between these three lots shall not exceed 15%. 4.8 Analytical Specificity Based on the characteristics of the analyte, the manufacturer shall analyze potential ......Source: Above contents are excerpted from the full-copy PDF -- translated/reviewed by: www.ChineseStandard.net / Wayne Zheng et al.
